January 12, 2015 / 12:45 PM / 4 years ago

FDA asks Arrowhead to cut Hep B drug dosage in mid-stage trial

Jan 12 (Reuters) - Drug developer Arrowhead Research Corp said the U.S. Food and Drug Administration asked the company to reduce the dosage of its experimental Hepatitis B treatment and requested additional data from the drug’s mid-stage trial.

The company’s shares fell 19 pct premarket on Monday.

Arrowhead said its ongoing mid-stage trial would continue as planned and that it expected to file with Asian and European agencies to begin additional mid-stage studies in coming weeks. (Reporting by Anjali Rao Koppala in Bangalore; Editing by Saumyadeb Chakrabarty)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below